Abstract
Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcinogenesis by inducing epithelial–mesenchymal transition (EMT), angiogenesis, and other signaling pathways. Overexpression of GLI1 is thought to be an indicator of poor prognosis as well as a potential therapeutic target for cancers. GLI inhibitors such as zerumbone, GANT61, resveratrol, and cyclopamine depress the Hh pathway in vitro and in vivo cancer research, and other non-canonical pathways may also activate expression of GLI1. Here, we summarize GLI function in carcinogenesis and cancer-targeted therapy.
Keywords: Hedgehog signaling, GLI proteins, carcinogenesis, targeted therapy, non-canonical pathways, mutation.
Graphical Abstract
Current Cancer Drug Targets
Title:Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Volume: 18 Issue: 6
Author(s): Jie Wu, Dingxin Di, Chen Zhao, Yingyi Liu, Hongxia Chen, Yan Gong, Xianda Zhao and Honglei Chen*
Affiliation:
- Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan 430071,China
Keywords: Hedgehog signaling, GLI proteins, carcinogenesis, targeted therapy, non-canonical pathways, mutation.
Abstract: Glioma-associated oncogenes (GLIs) are zinc finger protein family members and downstream regulatory factors of the classic Hedgehog (Hh) signaling pathway. GLI proteins influence the growth and development of organisms and aid in tissue repair. However, aberrant expression of the GLI family member GLI1 promotes carcinogenesis by inducing epithelial–mesenchymal transition (EMT), angiogenesis, and other signaling pathways. Overexpression of GLI1 is thought to be an indicator of poor prognosis as well as a potential therapeutic target for cancers. GLI inhibitors such as zerumbone, GANT61, resveratrol, and cyclopamine depress the Hh pathway in vitro and in vivo cancer research, and other non-canonical pathways may also activate expression of GLI1. Here, we summarize GLI function in carcinogenesis and cancer-targeted therapy.
Export Options
About this article
Cite this article as:
Wu Jie , Di Dingxin , Zhao Chen , Liu Yingyi , Chen Hongxia , Gong Yan , Zhao Xianda and Chen Honglei *, Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy, Current Cancer Drug Targets 2018; 18 (6) . https://dx.doi.org/10.2174/1568009618666171129223533
DOI https://dx.doi.org/10.2174/1568009618666171129223533 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Blood-Brain Barrier Penetration and Drug Development from an Industrial Point of View
Current Medicinal Chemistry - Central Nervous System Agents Inhibition of Autophagy Strengthens Celastrol-Induced Apoptosis in Human Pancreatic Cancer In Vitro and In Vivo Models
Current Molecular Medicine Novel and Emerging Targeted Therapies of Colorectal Cancer
Current Clinical Pharmacology The Scatter Factor Signaling Pathways as Therapeutic Associated Target in Cancer Treatment
Current Medicinal Chemistry Nanomedicinal Approach of Getting Across the Brood-Brain Barrier with Nanomedicinal Nanoparticles
Current Medicinal Chemistry Apoptotic Signaling Pathways as a Target for the Treatment of Liver Diseases
Mini-Reviews in Medicinal Chemistry Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets When Neighbors Talk: Colon Cancer Cell Invasion and Tumor Microenvironment Myofibroblasts
Current Drug Targets New Perspectives in Glioblastoma: Nanoparticles-based Approaches
Current Cancer Drug Targets Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design β-Lactone Derivatives and Their Anticancer Activities: A Short Review
Current Topics in Medicinal Chemistry Update on Laser Photochemotherapy: An Alternative for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Mesenchymal Stem Cells: Key Actors in Tumor Niche
Current Stem Cell Research & Therapy Editorial (Thematic Issue: Chemical and Biological Technology for In Vivo and Molecular Imaging)
Current Topics in Medicinal Chemistry Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry DNMT Inhibitors in Cancer, Current Treatments and Future Promising Approach: Inhibition of Specific DNMT-Including Complexes
Epigenetic Diagnosis & Therapy (Discontinued)